Adjuvant Therapy, Stage II Colon Cancer, Stage III Colon Cancer
Conditions
Keywords
Current status, Chemotherapy regimen, Chemotherapy time, Efficacy, Safety, Adjuvant therapy, Stage II-III colon cancer, RWS(Real World Study)
Brief summary
Background: 1. . The incidence and mortality of colon cancer are high in China and in the world. 2. . The treatment of many patients in the real world is not standardized, and there are problems such as over-treatment or under-treatment. To explore the adjuvant treatment of colon cancer in the Chinese population, this study will retrospectively analyze real-world data on adjuvant therapy for colon cancer in Chinese patients after radical surgery. The purpose of research: 1. . Current status of adjuvant therapy for stage II-III colon cancer in the real world: chemotherapy regimen, chemotherapy time, efficacy, safety, etc. 2. . Comparison of efficacy and safety of different adjuvant chemotherapy time (\<3 months vs. \>=3 months) in high-risk stage II and III colon cancer patients in the real world 3. . Comparison of efficacy and safety of different adjuvant chemotherapy regimens (XELOX vs. FOLFOX) in high-risk stage II and III colon cancer patients in the real world
Interventions
None listed
Sponsors
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients who are sick after January 2010 * Age is older than 18 * Surgical pathology confirmed TNM stage II-III (AJCC 7th edition) colon cancer
Exclusion criteria
* Combine other tumors * Pathological information is not clear * Researchers believe that other reasons are not suitable for enrollment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of patients with chemotherapy regimen for adjuvant therapy after stage II and stage III colon cancer | From patients after stage II and stage III colon cancer radical resection to until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months. | Percentage of patients with chemotherapy regimen for adjuvant therapy after stage II and stage III colon cancer |
| Percentage of patients with different chemotherapy time for adjuvant therapy for stage II and stage III colon cancer | From patients after stage II and stage III colon cancer radical resection to until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months. | Percentage of patients with different chemotherapy time for adjuvant therapy for stage II and stage III colon cancer |
| Percentage of Participants with treatment-related Adverse Events as Assessed by CTCAE v4.0 for adjuvant therapy for stage II and stage III colon cancer | From patients after stage II and stage III colon cancer radical resection to until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months. | Percentage of Participants with treatment-related Adverse Events as Assessed by CTCAE v4.0 for adjuvant therapy for stage II and stage III colon cancer |
Countries
China
Contacts
Primary ContactYing Yuan, Ph.D&MD
Outcome results
None listed